Primary Outcome of 21-Day Organ Support–Free Days and Survival to Hospital Discharge
heart failure, critically ill, peripheral artery disease
PERIPHERAL ARTERY DISEASE, CRITICALLY ILL, CARDIOVASCULAR DISEASE, CEREBROVASCULAR DISEASE, HEART FAILURE, HYPERTENSION, CORONARY ARTERY DISEASE
Abbreviations: CrI, credible interval; NA, not applicable; OR, odds ratio.Composite ordinal scale consisting of survival to hospital discharge and days free of organ support to day 21. An OR greater than 1 indicates a benefit from treatment. Probabilities of superiority (proportional OR >1), inferiority (proportional OR <1), and futility (proportional OR <1.2) are computed from the posterior distribution of the proportional OR for P2Y12 inhibitor compared with no P2Y12 inhibitor on the outcome.The model incorporated dynamic borrowing from 562 noncritically ill participants in the original ACTIV-4a study. The mean treatment effect in each group was assumed to follow a hierarchical normal distribution with the same mean, which created a dynamic amount of borrowing, depending on the similarity across groups.Effect of P2Y12 inhibitor on organ support–free days without dynamic borrowing from the critically ill cohort yielded an adjusted OR of 1.09 (95% CrI, 0.86-1.38), with a posterior probability of superiority of 76.8%.Adjusted for age, sex, enrollment epoch, cardiovascular disease (composite of hypertension, heart failure, coronary artery disease, peripheral artery disease, and cerebrovascular disease), sodium-glucose cotransporter 2 assignment, and baseline mechanical ventilation; study country and site are treated as nested random effects.Effect of P2Y12 inhibitor on survival to hospital discharge without dynamic borrowing from the critically ill cohort yielded an adjusted OR of 1.16 (95% CrI, 0.84-1.62), with a posterior probability of superiority of 81.1%.